VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 264 filers reported holding VAXCYTE INC in Q2 2024. The put-call ratio across all filers is 0.45 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $61,034,960 | -26.3% | 808,303 | -33.3% | 1.92% | -28.3% |
| Q1 2024 | $82,839,742 | +2.3% | 1,212,703 | -6.0% | 2.67% | -10.3% |
| Q4 2023 | $81,009,802 | -1.9% | 1,289,965 | -20.4% | 2.98% | +14.0% |
| Q3 2023 | $82,564,812 | -4.0% | 1,619,553 | -6.0% | 2.61% | -7.2% |
| Q2 2023 | $86,014,309 | +73.9% | 1,722,353 | +30.5% | 2.81% | +72.2% |
| Q1 2023 | $49,472,775 | -24.3% | 1,319,978 | -3.1% | 1.63% | -25.4% |
| Q4 2022 | $65,321,230 | – | 1,362,278 | – | 2.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $59,882,148 | 46.04% |
| Darwin Global Management, Ltd. | 2,080,946 | $163,916,116 | 19.07% |
| RA Capital Management | 8,203,754 | $619,465,465 | 8.19% |
| ACUTA CAPITAL PARTNERS, LLC | 110,400 | $8,336,304 | 7.02% |
| COMMODORE CAPITAL LP | 1,305,000 | $98,540,550 | 6.73% |
| Saturn V Capital Management LP | 215,680 | $16,285,997 | 6.15% |
| Cormorant Asset Management, LP | 1,100,000 | $83,061,000 | 4.80% |
| Kynam Capital Management, LP | 753,240 | $56,877,152 | 4.39% |
| Novo Holdings A/S | 950,000 | $71,734,500 | 4.16% |
| Frazier Life Sciences Management, L.P. | 1,039,405 | $78,485,472 | 3.67% |